Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

NCT03011814 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Folliculotropic Mycosis Fungoides
Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides
Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Mycosis Fungoides
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Sezary Syndrome
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: Durvalumab
OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide

Sponsor

City of Hope Medical Center

Collaborators

[object Object]